Inspira Technologies Secures Second U.S. Patent for Oxygen Delivery System
Ticker: IINNW · Form: 6-K · Filed: Sep 13, 2024 · CIK: 1837493
Sentiment: bullish
Topics: patent, medical-technology, intellectual-property
TL;DR
Inspira gets another US patent for its oxygen delivery tech. IP moat growing!
AI Summary
Inspira Technologies Oxy B.H.N. Ltd. announced on September 13, 2024, that it has received a second U.S. patent approval for its Orbiting Blood Oxygenation Delivery System. This patent is for a novel method and system for delivering oxygenated blood to patients. The company, headquartered in Ra'anana, Israel, is focused on developing innovative medical technologies.
Why It Matters
This patent approval strengthens Inspira's intellectual property portfolio, potentially enhancing its competitive position and future commercialization prospects for its blood oxygenation technology.
Risk Assessment
Risk Level: low — The filing is an informational report of a patent approval, which is generally a positive development with low immediate risk.
Key Players & Entities
- Inspira Technologies Oxy B.H.N. Ltd. (company) — Registrant
- Orbiting Blood Oxygenation Delivery System (technology) — Subject of patent
- September 13, 2024 (date) — Date of press release
FAQ
What is the significance of the second U.S. patent approval for Inspira Technologies?
The second U.S. patent approval for the Orbiting Blood Oxygenation Delivery System strengthens Inspira's intellectual property and its position in the medical technology market.
When was the press release regarding the patent approval issued?
The press release was issued on September 13, 2024.
What is the name of the technology for which Inspira received a second U.S. patent?
The technology is the Orbiting Blood Oxygenation Delivery System.
Where is Inspira Technologies Oxy B.H.N. Ltd. headquartered?
Inspira Technologies Oxy B.H.N. Ltd. is headquartered at 2 Ha-Tidhar St., Ra'anana, 4366504, Israel.
What form is this SEC filing?
This SEC filing is a Form 6-K, Report of Foreign Private Issuer.
Filing Stats: 302 words · 1 min read · ~1 pages · Grade level 8.9 · Accepted 2024-09-13 16:05:47
Filing Documents
- ea0214460-6k_inspira.htm (6-K) — 11KB
- ea021446001ex99-1_inspira.htm (EX-99.1) — 11KB
- 0001213900-24-078554.txt ( ) — 23KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Inspira Technologies Oxy B.H.N. Ltd. Date: September 13, 2024 By: /s/ Dagi Ben-Noon Name: Dagi Ben-Noon Title: Chief Executive Officer 2